Andrew Davis Sells 5,360 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) SVP Andrew Davis sold 5,360 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $21,868.80. Following the completion of the sale, the senior vice president now owns 284,685 shares of the company’s stock, valued at $1,161,514.80. This trade represents a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ironwood Pharmaceuticals Trading Down 0.3 %

Shares of Ironwood Pharmaceuticals stock opened at $3.33 on Friday. The company has a market cap of $532.89 million, a PE ratio of -111.33 and a beta of 0.47. The company has a 50 day moving average of $4.23 and a 200-day moving average of $5.36. Ironwood Pharmaceuticals, Inc. has a 1-year low of $3.26 and a 1-year high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. During the same quarter in the previous year, the company earned $0.12 earnings per share. The firm’s revenue for the quarter was down 19.4% on a year-over-year basis. Research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Institutional Trading of Ironwood Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at $78,000. Vestcor Inc grew its holdings in shares of Ironwood Pharmaceuticals by 37.8% during the third quarter. Vestcor Inc now owns 159,466 shares of the biotechnology company’s stock worth $657,000 after purchasing an additional 43,703 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Ironwood Pharmaceuticals by 102.7% in the third quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company’s stock valued at $1,333,000 after buying an additional 164,006 shares during the period. Wolverine Trading LLC bought a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $51,000. Finally, Weiss Asset Management LP bought a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $893,000.

Analyst Upgrades and Downgrades

IRWD has been the subject of a number of research reports. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price objective for the company. Wells Fargo & Company decreased their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Finally, Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.